

The effect of intra-cerebroventricular injection of insulin on the levels of monoamines on the raphe magnus nucleus of non-diabetic and short-term diabetic rats in the formalin test

Shima Balali Dehkordi ¹, Javad Sajedianfard ^{1*}, Ali Akbar Owji ²

¹ Department of Basic Sciences, School of Veterinary Medicine, Shiraz University, Shiraz, Iran

² Department of Biochemistry, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran

ARTICLE INFO

Article type:
Original article

Article history:
Received: Oct 15, 2018
Accepted: Feb 24, 2019

Keywords:
Formalin test
Insulin
Microdialysis
Monoamines
Pain

ABSTRACT

Objective(s): Systemic and intracerebroventricular (ICV) injection of insulin possess analgesic effects. The raphe magnus nucleus (RMN) is part of the endogenous analgesia system. The objective of the present study was to evaluate the effects of ICV injection of insulin on the levels of monoamines and their related metabolites in the RMN during the formalin test in non-diabetic and short-term diabetic rats.

Materials and Methods: Sixty four adult male rats were used. Diabetes was induced by Streptozotocin (STZ) (60 mg/kg, IP); insulin (5 mU/animal, 5 µl) was injected into the left ventricle. Microdialysis was performed in each rat. Samples were collected at 15 min intervals. After taking the base sample of microdialysis, 50 µl of 2.5% formalin was injected into the plantar surface of the hind paw, and the level of nociception was recorded every 15 sec for 1 hr. Monoamines and their metabolites concentrations were measured using the HPLC-ECD method.

Results: Findings showed that ICV injection of insulin in non-diabetic rats increased the concentration of monoamines and their related metabolites in the RMN. In diabetic rats, injection of insulin decreased the concentrations of monoamines and their related metabolites in the RMN ($P < 0.05$). Our results determined that, at least in part, insulin is associated with antinociceptive effect in non-diabetic rats.

Conclusion: Based on the results, it seems that ICV injection of insulin in non-diabetic rats increased the activity of the central pain control pathways leading to antinociceptive response, but this condition was not seen in diabetic rats.

► Please cite this article as:

Balali Dehkordi Sh, Sajedianfard J, Owji AA. The effect of intra-cerebroventricular injection of insulin on the levels of monoamines on the raphe magnus nucleus of non-diabetic and short-term diabetic rats in the formalin test. Iran J Basic Med Sci 2019; 22:915-921. doi: 10.22038/ijbms.2019.35580.8485

Introduction

Pain pathways in the central nervous system (CNS) are complex and controlled by various mediators (1, 2, 3). Pain is controlled by certain pathways in the CNS. One of these paths is the descending serotonergic system originating from the nucleus raphe magnus (NRM) (3). The main function of NRM is pain mediation via sending projections to the dorsal horn of the spinal cord, which directly inhibits pain (4).

NRM is a subset of raphe nuclei collections (2, 5). NRM is located in the caudal pons and medulla, which receives descending afferents from the periaqueductal grey matter (PAG), the paraventricular hypothalamic nucleus, central nucleus of the amygdala, lateral hypothalamic area, parvocellular reticular nucleus, the prelimbic, infralimbic, and medial and lateral precentral cortices (2, 5). It has been documented that NRM receives noradrenergic projections from the locus coeruleus nucleus (6); and proposed that some factors can alter the pain threshold including gender, depression, individual differences, and endocrine hormones (7).

Insulin is produced by the beta cells of the pancreas (8). Streptozotocin (STZ) is a glucosamine-nitrosourea compound that is used to induce diabetes by destroying pancreatic beta cells (9).

Insulin could cross the blood-brain barrier (BBB) via a receptor-mediated transport mechanism (10-13). Previous studies have shown that there are insulin receptors throughout the brain (11, 14). There are several lines of evidence indicating that insulin is synthesized in the brain especially in the hippocampus, olfactory bulb, piriform cortex, and the Purkinje cells of the cerebellar cortex (15, 16).

It has been found that insulin reduces pain sensitivity in rats (17, 18). In our previous study, we demonstrated that intracerebroventricular (ICV) injection of insulin in diabetic rats increased pain sensitivity while in non-diabetic rats, it increased the pain threshold (19).

Despite the studies above, there is no information on the central analgesic mechanism of insulin. The NRM is part of the endogenous analgesia system and operated in the spinal cord to control pain (20). Measurement of NRM neurotransmitters by microdialysis is considered a valid method for evaluation of NRM function (21). So the objective of this study was to evaluate the effect of ICV insulin injection on the concentration of neurotransmitters such as serotonin, dopamine, norepinephrine, and their metabolites in the NRM during formalin test in non-diabetic and short-term diabetic rats.

*Corresponding author: Javad Sajedianfard. Department of Basic Sciences, School of Veterinary Medicine, Shiraz University, Shiraz, Iran. Tel: +98-71-3613 8622; Fax: +98-71-3228 6940; Email: sajedian@shirazu.ac.ir

Materials and Methods

Animals

Ethics: The protocol of this study was in accordance with the Ethics Committee of the School of Veterinary Medicine, Shiraz University, Shiraz, Iran (ethics committee code 93GCU3M1293).

Sixty-four male Sprague-Dawley adult rats (280 ± 30 g) were divided into eight groups (4 non-diabetic groups and 4 diabetic groups).

Animals were housed in standard Plexiglas boxes under a 12-hour light/dark cycle, with an ambient temperature of 22 ± 2 °C. They had free access to food and water.

Study design

The animals were divided into eight groups (n=8): group 1 (non-diabetic main control group) injected with normal saline (5 μ l, ICV and 50 μ l subcutaneously (SC) in the left hind paw); group 2 (non-diabetic control insulin group) injected with normal saline (5 μ l, ICV) and formalin (50 μ l, SC, in the left hind paw); group 3 (non-diabetic control formalin test group) injected with insulin (5 μ l, ICV) and normal saline (50 μ l, SC, in the left hind paw); group 4 (non-diabetic test group) injected with insulin (5 μ l, ICV) and formalin (50 μ l, SC, in the left hind paw); group 5 (diabetic control insulin group) injected with normal saline (5 μ l, ICV) and formalin (50 μ l, SC, in the left hind paw); group 6 (diabetic control formalin test group) injected with insulin (5 μ l, ICV) and normal saline (50 μ l, SC, in the left hind paw); group 7 (diabetic test group) injected with insulin (5 μ l, ICV) and formalin (50 μ l, SC, in the left hind paw); and group 8 (diabetic main control group) injected with normal saline (5 μ l, ICV and 50 μ l, SC, in the left hind paw).

Induction of diabetes

After 24 hr fasting, a single intraperitoneal (IP) injection of STZ (60 mg/kg) (Sigma Aldrich Company) that was dissolved in 0.01 mol/l citric acid solution (pH=4.5) was used to induce diabetes (22, 23). Non-diabetic rats received an equal volume of citrate buffer (pH=4.5). Three days after the STZ administration, the blood glucose levels from the tail vein were measured by a glucometer (ACCU - CHECK). Blood glucose higher than 250 mg/dl was considered as a diabetic state (22, 23). Forty-eight hours after establishing the diabetes, the formalin test and microdialysis were performed.

Preparation and calibration of the dialysis probe

Concentric microdialysis probes with active dialysis length of 1 mm were made based on Sharp and Zetterstrom's method (24). The dialysis membrane with spectra/pro hollow fiber: molecular weight cutoff: 6000

Da; 0.250 mm OD.

The probes were tested *in vitro* before being implanted in the rats' brain. In this way, the ability of probes for recovering monoamines was determined (25). Recovery was about 25%.

Probe and guide cannula implantation

Rats were anesthetized by the intraperitoneal injection of sodium pentobarbital (50 mg/kg). The guide cannula was implanted in the lateral ventricle (AP=- 0.8 mm, L=+1.5 mm and DV=-3.6 mm) (26). The microdialysis probe was implanted in NRM (AP=-10.8 mm, L=0 mm, DV=-10.6 mm). Microdialysis and formalin test were done 24 hr after the implantation of probe and guide cannula (27, 28).

Artificial cerebrospinal fluid (ACSF) and insulin preparation

The components of ACSF (in mmol) were included: NaCl 114, NaOH 1, CaCl₂ 1, MgSO₄ 2, NaH₂PO₄ 1.25, KCl 3, NaHCO₃ 26, Glucose 10 and pH= 7.4.

Insulin (bovine insulin) (Sigma Aldrich, Germany) was dissolved in saline and injected intracerebroventricularly.

Microdialysis and formalin test

Microdialysis was done 24 hr after stereotaxic surgery (27, 28). ACSF was continuously perfused into the microdialysis probe with a flow rate of 2 μ l/min by a syringe pump (WPI, SP 210). Samples were collected at 15 min intervals. The perfused fluid was collected in microtubes located in ice. Insulin (5 mU/animal, 5 μ l) was injected into the left ventricle at the rate of 1 μ l / min by a Hamilton syringe (10 μ l) in diabetic rats. Other animals received normal saline. Two base samples were collected (S1= without insulin effect, S2= with insulin effect). The formalin test was performed 10 min after the insulin injection. Dialysis samples were collected during the formalin test. Samples were stored at -80 °C until HPLC analysis.

To perform the formalin test, 50 μ l of 2.5% formalin was injected subcutaneously into the plantar region of the left hind paw using a 27-gauge needle. Normal saline was injected instead of formalin in related groups. The level of nociception was recorded every 15 sec for one hour (29). In the formalin test, the mean of pain scores during the early phase (first 5 min), and the late phase (20–60 min) were recorded.

Histological verification

At the end of the microdialysis experiment, each animal was euthanized with an overdose of diethyl ether. Brains were removed and placed in formalin; then, histologic sections were provided (Figure 1).



Figure 1. A: Example of histological verification of the cannula placement for microinjection of insulin/normal saline into the lateral ventricle. B: Example of histological verification of the dialysis probe placement in NRM




Figure 2. Concentration of norepinephrine (NE) and its metabolite (HMPG) in diabetic and non-diabetic groups. Sample numbers are according to collection of microdialysis samples every 15 min.

* A significant difference between non-diabetic control insulin and test groups ($P < 0.05$)
 \$ A significant difference between non-diabetic and diabetic test groups ($P < 0.05$)
 # A significant difference between diabetic control insulin and test groups ($P < 0.05$)
 & A significant difference between non-diabetic and diabetic control insulin groups ($P < 0.05$)

The position of guide cannula and probe tracing were verified according to rat brain atlas (26).

High-pressure liquid chromatography (HPLC) analysis

Norepinephrine, serotonin, dopamine, and their metabolites were analyzed using HPLC with electrochemical detection (ECD). Dialysate samples were injected into the column (Reverse-phase column, Eurospher, 100- 5 C18, 250× 4.6mm) connected to a pump (Knauer) and the electrochemical detector (Amperometric detector EC 3000). Autochro data module software was used for drawing the graph and data analysis. The oxidizing potential of the working electrode was set at +750 mV versus Ag| Ag Cl reference electrode.

The mobile phase composition contained 1-octanesulfonic acid 360 mg, sodium phosphate 8.4 g, EDTA 30 mg and 16% of methanol in 1000 ml H₂O (pH=3.5). The flow rate of mobile phase was 1.0 ml/min.

Data analysis

The Statistic analysis was done by SPSS 16.0 software. Two-way repeated measure ANOVA was used for the analysis. Results are expressed as mean±SEM. $P < 0.05$




Figure 3. Concentration of dopamine and its metabolite (DOPAC) in diabetic and non-diabetic groups. Sample numbers are according to collection of microdialysis samples every 15 min

* A significant difference between non-diabetic control insulin and test groups ($P < 0.05$)
 \$ A significant difference between non-diabetic and diabetic test groups ($P < 0.05$)
 # A significant difference between diabetic control insulin and test groups ($P < 0.05$)
 & A significant difference between non-diabetic and diabetic control insulin groups ($P < 0.05$)

was considered as statistical significance.

Results

Microdialysis results

The mean± SEM concentration of norepinephrine and its metabolite (MHPG), serotonin and its metabolite (HIAA) and dopamine and its metabolite (DOPAC) in each group are illustrated in Figures 2, 3 and 4.

ICV injection of insulin increased the concentration of norepinephrine in the non-diabetic rats

There was no significant difference between the non-diabetic control groups (group 1 with 3).

The norepinephrine concentration was higher in the non-diabetic main test group (group 4) than in non-diabetic control insulin group (group 2). A significant difference was observed between these groups in the third, fourth, fifth, and sixth samples ($P < 0.05$) (Figure 2A). There was no significant difference between diabetic control groups (groups 6 and 8) (Figure 2A).

The norepinephrine concentration was higher in the diabetic control insulin group (group 5) than in diabetic main test group (group 7). A significant difference was

observed between these groups in the third and fourth samples ($P < 0.05$) (Figure 2A). Our findings showed a significant difference between non-diabetic and diabetic main test groups (4 and 7 groups) in all samples except for the first and second base samples (Figure 2A).

There was significant difference between diabetic and non-diabetic control insulin groups in the first phase of the formalin test (5 and 2 groups) ($F(37.30, 229.14) = 48.58, P < 0.05$).

ICV injection of insulin increased the concentration of MHPG (3-Methoxy-4-hydroxyphenylglycol) in the non-diabetic rats

There was no significant difference between non-diabetic control groups (groups 1 and 3) (Figure 2B).

MHPG concentration was higher in the non-diabetic main test group (group 4) than in non-diabetic control insulin group (group 2). A significant difference was observed between these groups in the third, fourth, fifth, and sixth samples ($P < 0.05$) (Figure 2B).

There was no significant difference between diabetic control groups (groups 6 and 8) (Figure 2B).

MHPG concentration was higher in the diabetic control insulin group (group 5) than in diabetic main test group (group 7). A significant difference was observed between these groups in the third and fourth samples ($P < 0.05$) (Figure 2B).

There was a significant difference between non-diabetic and diabetic main test groups (4 and 7 groups) in all samples except for the first and second base samples ($P < 0.05$) (Figure 2B).

There was significant difference between diabetic and non-diabetic control insulin groups in the first phase of the formalin test (5 and 2 groups) ($F(20.12, 123.60) = 9.55, P < 0.05$).

ICV injection of insulin increased the concentration of dopamine in the non-diabetic rats

There was no significant difference between non-diabetic control groups (group 1 and 3).

The dopamine concentration was higher in the non-diabetic main test group (group 4) than in non-diabetic control insulin group (group 2). A significant difference was observed between these groups in the third, fourth, and fifth samples ($P < 0.05$) (Figure 3C).

There was no significant difference between diabetic control groups (group 6 and 8) (Figure 3C).

The dopamine concentration was higher in the diabetic control insulin group (group 5) than in diabetic main test group (group 7). A significant difference was observed between these groups in the third and fourth samples ($P < 0.05$) (Figure 3C).

There was a significant difference between non-diabetic and diabetic main test groups (4 and 7 groups) in all samples except for the first and second base samples and the sixth sample (Figure 3C).

There was significant difference between diabetic and non-diabetic control insulin groups in the first phase of the formalin test (groups 5 and 2) ($F(24.96, 153.31) = 5.58, P < 0.05$).

ICV injection of insulin increased the concentration of DOPAC (3, 4 hydroxyphenyl acetaldehyde) in the non-diabetic rats

There was no significant difference between non-

diabetic control groups (group 1 and 3).

The DOPAC concentration was higher in the non-diabetic main test group (group 4) than in non-diabetic control insulin group (group 2). A significant difference was observed between these groups in the third, fourth, and fifth samples ($P < 0.05$) (Figure 3D).

There was no significant difference between diabetic control groups (group 6 and 8) (Figure 3D).

The DOPAC concentration was higher in diabetic control insulin group (group 5) than in diabetic main test group (group 7). A significant difference was observed between these groups in the third and fourth samples ($P < 0.05$) (Figure 3D).

There was a significant difference between non-diabetic and diabetic main test groups (4 and 7 groups) in all samples except for the first and second base samples (Figure 3D).

There was significant difference between diabetic and non-diabetic control insulin groups in the first phase of the formalin test (5 and 2 groups) ($F(22.92, 140.78) = 12.92, P < 0.05$).

ICV injection of insulin increased the concentration of serotonin in the non-diabetic rats

There was no significant difference between non-diabetic control groups (groups 1 and 3) (Figure 4E).

The serotonin concentration was higher in the non-diabetic main test group (group 4) than in non-diabetic control insulin group (group 2). A significant difference was observed between these groups in the third, fourth, fifth, and sixth samples ($P < 0.05$) (Figure 4E).

There was no significant difference between diabetic control groups (groups 6 and 8) (Figure 4E).

The serotonin concentration was higher in the diabetic control insulin group (group 5) than in diabetic main test group (group 7). A significant difference was observed between these groups in the third and fourth samples ($P < 0.05$) (Figure 4E).

There was a significant difference between the non-diabetic and diabetic main test groups (4 and 7 groups) in all samples except for the first, and second base and eighth samples ($P < 0.05$) (Figure 4E).

There was a significant difference between diabetic and non-diabetic control insulin groups in the first phase of the formalin test (groups 5 and 2) ($F(49, 301) = 4.84, P < 0.05$).

ICV injection of insulin increased the concentration of 5- HIAA (5-hydroxyindoleacetic Acid) in the non-diabetic rats

There was no significant difference between the non-diabetic control groups (groups 1 and 3) (Figure 4F).

The HIAA concentration was higher in the non-diabetic main test group (group 4) than in non-diabetic control insulin group (group 2). A significant difference was observed between these groups in the third, fourth, fifth, and sixth samples ($P < 0.05$) (Figure 4F).

There was no significant difference between diabetic control groups (groups 6 and 8) (Figure 4F).

The HIAA concentration was higher in diabetic control insulin group (group 5) than in diabetic main test group (group 7). A significant difference was observed between these groups in the third and fourth samples ($P < 0.05$) (Figure 4F).




Figure 4. Concentration of serotonin and its metabolite (HIAA) in diabetic and non-diabetic groups. Sample numbers are according to collection of microdialysis samples every 15 min
 * A significant difference between non-diabetic control insulin and test groups ($P < 0.05$)
 \$ A significant difference between non-diabetic and diabetic test groups ($P < 0.05$)
 # A significant difference between diabetic control insulin and test groups ($P < 0.05$)
 & A significant difference between non-diabetic and diabetic control insulin groups ($P < 0.05$)

There was a significant difference between the non-diabetic and diabetic main test groups (4 and 7 groups) in all samples except for the first, and second base and eighth samples ($P < 0.05$) (Figure 4F).

There was a significant difference between the diabetic and non-diabetic control insulin groups in the first phase of the formalin test (5 and 2 groups) ($F(29.58, 181.71) = 4.21, P < 0.05$).

Discussion

Several studies have suggested an analgesic effect for insulin (17, 18, 30, 31). It has been proposed that insulin exert its analgesic effects through affecting the analgesic pathways, including dopaminergic, serotonergic, and opioidergic systems (18). We recently reported that ICV injection of insulin exerted an analgesic effect on rats. Moreover, we showed that ICV injection of insulin in diabetic rats could increase the pain responses in the formalin test (19).

Therefore, in the current study, we aimed to clarify the mechanisms involved in this effect, focusing on norepinephrine, serotonin, dopamine, and their metabolites in the NRM in the formalin test.

Our results demonstrated that the concentration of norepinephrine and its metabolite (MHPG), serotonin and its metabolite (5- HIAA), as well as dopamine and its metabolite (DOPAC) in the NRM, increased after the formalin-induced pain response. We showed that the concentration of the aforementioned neurotransmitters and also pain response in non-diabetic control insulin group, was higher than the short-term diabetic control insulin group.

Peripheral nerves such as Aδ and C fibers conduct impulses to the lumbosacral cord and the paragigantocellularis in the rostroventral medulla (32). The stimulation of the paragigantocellularis increases the release of glutamate and aspartate in the locus coeruleus (LC), leading to the stimulation of the noradrenergic neurons within the locus coeruleus (33, 34). Norepinephrine activates the α₂- adrenoceptors in the descending noradrenergic pathway of the spinal cord, (34, 35). NRM receives noradrenergic projections from LC (6). Therefore, it is anticipated that the stimulation of noradrenergic neurons within LC increases the norepinephrine and its metabolite concentrations in NRM. The body of evidence demonstrated that the stimulation of α₁-adrenoceptors in the raphe magnus neurons led to the increases in the neuronal activity of NRM, resulting in inhibition of nociception (6, 36).

NRM is the origin of the serotonergic pathway modulating the transmission of noxious inputs at the spinal level (37). The periaqueductal gray and nucleus paragigantocellularis send serotonin projection to the raphe nucleus, playing a role in pain relief (38).

Mesencephalic raphe nuclei contain substance P, CCK, VIP, dopamine, and neurotensin (39- 42). There are numerous dopamine-containing cell bodies in the dorsal and median raphe nuclei (43).

The antinociceptive action of dopamine is mediated by D2 receptors in the rats' nucleus raphe Magnus (44).

It has been reported that in the diabetic state, in response to cell hypoglycemia, endogenous opiates are released acutely along with ACTH (45). Raz *et al.* suggested that in diabetes, the pain threshold was maintained due to the compensatory secretion of endogenous opiates (45). Hyperglycemia in diabetes, changes the function of the hypothalamic-pituitary and endogenous opioid systems, leading to the acute release of opioids (46). It shows that diabetes increases the level of serotonin in the CNS (47) resulting in an increased pain threshold (48- 50).

The results of the present study showed that non-diabetic and diabetic control groups had high levels of norepinephrine, dopamine, and their metabolites in the NRM at the time of saline injection in the hind paw when compared after the formalin injection. These results are in line with those of Sajedianfard *et al.* (51). The increased levels of these neurotransmitters are due to the stress imposed by the injection. It is known that noradrenergic neurons in the locus coeruleus respond forcefully to certain types of stress (52). Fernstrom reported that stressful stimuli increased norepinephrine, serotonin, and dopamine synthesis as well as the turnover in the rats' brain (53).

In this study, ICV injection of insulin ten minutes before the induction of pain increased the norepinephrine, MHPG, serotonin, 5- HIAA, dopamine, and DOPAC

concentrations in the non-diabetic main test group (group 4) compared with the non-diabetic control insulin group (group 2); this is in agreement with the results of our previous study (19). Thus, ICV injection of insulin may indirectly activate noradrenergic, serotonergic, and dopaminergic descending pain control pathways, thereby relieving pain in non-diabetic rats. It was reported that serotonin microinjection into the NRM produced significant analgesic effects. (54). Previous studies proposed a central role for dopamine in modulating the pain perception and analgesia within supraspinal regions (55, 56). It has been suggested that painful symptoms of Parkinson's disease may be due to the decrease in the dopamine levels (56).

Study showed that ICV injection of insulin through the activation of central dopaminergic, serotonergic, and opioidergic pathways attenuated specifically the second phase of formalin-induced nociception in non-diabetic mice (18). Serotonin, dopamine, opioidergic receptors, NMDA receptors, and potassium and calcium channels may have an important role in the analgesic effect of insulin (17).

In the present study, ICV injection of insulin ten minutes before the induction of pain, decreased the concentration of norepinephrine, MHPG, serotonin, 5- HIAA, dopamine, and DOPAC in the diabetic main test group (group 7) compared with the diabetic control insulin group (group 5). The reduction of norepinephrine, serotonin, dopamine, and their metabolites was consonant with the increasing pain response (19). Our previous study showed that ICV injection of insulin in diabetic rats could not reduce the pain response and, partially, decreased the pain threshold (especially 5 to 25 min after the formalin injection) (19). Researchers reported that the analgesic effect of insulin on diabetic mice was less than that observed in non-diabetic mice due to the distribution of pain control pathways such as dopaminergic (57), serotonergic, and opioidergic pathways (18). Researchers showed that although insulin improved the pain responses of STZ-diabetic rats, it did not alter the levels of norepinephrine and serotonin in the brain stem and spinal cord. They concluded that the antinociceptive effects of insulin were not mediated by the noradrenergic and serotonergic systems (23). These differences may be related to the model of diabetes induction in our study in which we used a short-term model of diabetes with other previous studies.

Conclusion

In the present study, ICV injection of insulin increased the concentration of serotonin, norepinephrine, dopamine, and their metabolites in the NRM of non-diabetic rats. The concentrations of these neurotransmitters and their metabolites in the diabetic rats were decreased after ICV injection of insulin.

Based on these results, it seems that ICV injection of insulin in non-diabetic rats, increased the activity of the central descending pain control pathways, but this condition was not seen in the diabetic rats.

Acknowledgment

The results of this paper were from a PhD thesis which

was supported by the School of Veterinary Medicine, Shiraz University, Shiraz, Iran.

References

1. Amini-Khoei H, Amiri S, Mohammadi-Asl A, Alijanpour S, Poursaman S, Haj-Mirzaian A, Rastegar M, Mesdaghinia A, Banafshe HR, Sadeghi E, Samiei E, Mehr SE, Dehpour AR. Experiencing neonatal maternal separation increased pain sensitivity in adult male mice: involvement of oxytocinergic system. *Neuropeptides* 2017; 61, 77-85.
2. Hermann DM, Luppi PH, Peyron C, Hinckel P, Jouvét M. Afferent projections to the rat nuclei raphe magnus, raphe pallidus and reticularis gigantocellularis pars demonstrated by iontophoretic application of cholera toxin (subunit b). *J Chem Neuroanat* 1977; 13: 1-21.
3. Millan MJ. Descending control of pain. *Prog Neurobiol* 2002; 66: 355-474.
4. Calvino B, Grilo RM. Central pain control. *Joint Bone Spine* 2006; 73: 10- 16.
5. Hassanipour M, Amini-Khoei H, Shafaroodi H, Shirzadian A, Rahimi N, Imran-Khan M, et al. Atorvastatin attenuates the antinociceptive tolerance of morphine via nitric oxide dependent pathway in male mice. *Brain Res Bull* 2016; 125, 173-180.
6. Samuels ER, Szabadi E. Functional neuroanatomy of the noradrenergic locus coeruleus: its roles in the regulation of arousal and autonomic function part I: principles of functional organisation. *Curr Neuropharmacol* 2008; 6: 235-253.
7. Guneli E, Gumustekin M, Ates M. Possible involvement of ghrelin on pain threshold in obesity. *Med Hypotheses* 2010; 74: 452-454.
8. Hoang Do O, Thorn P. Insulin secretion from beta cells within intact islets: Location matters. *Clin Exp Pharmacol Physiol* 2015; 42: 406-414.
9. Deeds MC, Anderson JM, Armstrong AS, Gastineau DA, Hiddinga HJ, Jahangir A, Eberhardt NL, Kudva YC. Single dose streptozotocin-induced diabetes: considerations for study design in islet transplantation models. *Lab Anim* 2011; 45: 131-140.
10. Banks WO, Erickson MA. Insulin in the brain: there and back again. *Pharmacol Ther* 2012; 136: 82-93.
11. Blazquez E, Velazquez E, Hurtado-Carneiro V, Ruiz-Albusac JM. Insulin in the brain: its pathophysiological implications for States related with central insulin resistance, type 2 diabetes and Alzheimer's disease. *Front Endocrinol (Lausanne)* 2014; 5:1- 21.
12. Duarte AI, Moreira PI, Oliveira CR. Insulin in central nervous system: more than just a peripheral hormone. *J Aging Res* 2012; Article ID 384017: 1-21.
13. Plum L, Schubert M, Bruning JC. The role of insulin receptor signaling in the brain. *Trends Endocrinol Metab* 2005; 16: 59-65.
14. Schulingkam RP, Pagano TC, Hung D, Raffa RB. Insulin receptors and insulin action in the brain: review and clinical implications. *Neurosci Biobehav Rev* 2000; 24: 855-872.
15. Zhao WQ, Alkon DC. Roles of the brain insulin receptor in spatial learning. *Mol Cell Endocrinol* 2001; 177: 125-134.
16. Hui L, Pei D, Zhang Q, Guan Q, Zhang G. The neuroprotection of insulin on ischemic brain injury in rat hippocampus through negative regulation of JNK signaling pathway by PI3K/Akt activation. *Brain Research* 2005; 1052: 1- 9.
17. Anuradha K, Hota D, Pandhi P. Possible mechanisms of insulin antinociception. *Methods Find Exp Clin Pharmacol* 2004; 26: 5-8.
18. Takeshita N, Yamaguchi I. Insulin attenuates formalin-induced nociceptive response in mice through a mechanism

- that is deranged by diabetes mellitus. *J Pharmacol Exp Ther* 1997; 28: 315-321.
19. Balali Dehkordi Sh, Sajedianfard J, Owji AA. The effect of intra-cerebroventricular injection of insulin on nociception of formalin test in non-diabetic and short-term diabetic rat models. *Iran J Vet Res* 2017; 18: 108- 112.
 20. Ossipov MH, Dussor GO, Porreca F. Central modulation of pain *J Clin Investig* 2010; 120: 3779-3787.
 21. Davies MI, Cooper JD, Desmond S, Lunte, C, Lunte S. Analytical considerations for microdialysis sampling. *Adv Drug Deliv. Rev* 2000; 45: 169- 188.
 22. Gomar AHA, Mirazi N, Gomar M. Antinociceptive effect of *Brassica juncea* on peripheral neuropathy induced by diabetes in rat. *Arak Med Uni J* 2014; 17: 63-70.
 23. Silva, L. Central effects of insulin and IGF1 in diabetic neuropathy. MSc Thesis, 2010. pp. 74.
 24. Sharp T, Zetterstrom T. In vivo measurement of monoamine neurotransmitter release using brain microdialysis. In: Stamford, J.A. (Ed.), *Monitoring Neuronal Activity: A Practical Approach*. Oxford University Press, London, 1992; pp. 147-179.
 25. Robert F, Lambas-Senas L, Ortemann C, Pujol JF, Renaud B. Microdialysis monitoring of 3, 4-dihydroxy phenylalanin accumulation changes in tyrosine hydroxylase activity of rat locus coeruleus. *J Neurochem* 1993; 60: 721- 729.
 26. Paxinos G, Watson C. *The rat brain in stereotaxic coordinates*. 6th ed. Sydney: Academic Press 2006; pp 112, 278.
 27. Mobasher MA, Sajedianfard J, Jamshidzadeh A, Naghdi N, Namvaran MM. The effects of tramadol on norepinephrine and MHPG releasing in locus coeruleus in formalin test in rats: a brain stereotaxic study. *Iran J Basic Med Sci* 2014; 17: 419-425.
 28. Rahimi K, Sajedianfard J, Owji AA. The effect of intracerebroventricular injection of CGRP on pain behavioral responses and monoamines concentrations in the periaqueductal gray area in rat. *Iran J Basic Med Sci* 2018; 21: 395- 399.
 29. Dubbuisson D, Dennis SG. The formalin test: a quantitative study of the analgesic effects of morphine, meperidine and brain stem stimulation in rats and cats. *Pain* 1977; 4: 161-174.
 30. Gordon AE, Meldrum B S. Effect of insulin on brain 5-hydroxytryptamine and 5-hydroxy-indole-acetic acid of rat. *Biochem Pharmacol* 1970; 19: 3042-3044.
 31. Gupta G, Azam M, Baquer N Z. Effect of experimental diabetes on the catecholamine metabolism in rat brain. *J Neurochem* 1992; 58: 95-100.
 32. Raina GS, Khurana A, Soni M. Role of thiamine and its moieties in growth rate of diatom SP. Nociceptive pain current updates in mechanisms and pathways. *Int J Pharma Bio Sci* 2011; 2: 313- 331.
 33. Ennis M, Aston-Jones G, Shiekhhattar R. Activation of locus coeruleus neurons by nucleus paragigantocellularis or noxious sensory stimulation is mediated by intracoerulear excitatory amino acid neurotransmission. *Brain Res* 1992; 598: 185- 195.
 34. Singewald N, Philippu A. Release of neurotransmitters in the locus coeruleus. *Prog. Neurobiol* 1998; 56: 237- 267.
 35. Singewald N, Zhou GY, Schneider C. Releasing of excitatory and inhibitory amino acid from the locus coeruleus of conscious rats by cardiovascular stimuli and various forms of acute stress. *Brain Res* 1995; 704: 42- 50.
 36. Bie B, Fields HL, Williams JT, Pan ZZ. Roles of α 1- and α 2-adrenoceptors in the nucleus raphe magnus in opioid analgesia and opioid abstinence-induced hyperalgesia. *J Neurosci* 2003; 23:7950-7957.
 37. Kandel E, Schwartz JH, Jessell TM, Siegelbaum SA, Hudspeth AJ. *Principals of Neural Science*. 5th ed. New York City: Mc Graw Hill; 2013 p 530- 555.
 38. Beitz A.J. The sites of origin of brain stem neurotensin and serotonin projections to the rodent nucleus raphe magnus. *J Neurosci* 1982; 2: 829- 842.
 39. Uhl GR, Goodman RR, Snyder SH. Neurotensin-containing cell bodies, fibers and nerve terminals in the brain stem of the rat: Immunohistochemical mapping. *Brain Res* 1979; 167: 77- 91.
 40. Moss MS, Glazer EJ, Basbaum AI. Enkephalin-immunoreactive perikarya in the cat raphe dorsalis. *Neurosci Lett* 1981; 21: 33- 37.
 41. Moss MS, Glazer EJ, Basbaum AI. The peptidergic organization of the cat periaqueductal gray. I. The distribution of immunoreactive enkephalin-containing neurons and terminals. *J Neurosci* 1983; 3: 603-616.
 42. Magoul R, Onteniente B, Oblin A, Calas A. Inter- and intracellular relationship of substance P containing neurons with serotonin and GABA in the dorsal raphe nucleus: Combination of autoradiographic and immunocytochemical techniques. *J Histochem Cytochem* 1986; 34: 735-742.
 43. Trulsson ME, Cannon MS, Raese JD. Identification of dopamine-containing cell bodies in the dorsal and median raphe nuclei of the rat brain using tyrosine hydroxylase immunocytochemistry. *Brain Res* 1985; 15:229-234.
 44. Phillips S, Gelgor L, Mitchell D. Antinociceptive action of dopamine agonists in the nucleus raphe magnus of rats is mediated by D2 receptors. *Pain* 1992; 319: 66- 75.
 45. Raz I, Hasdai D, Seltzer Z, Melmed RN. Effect of hyperglycemia on pain perception and on efficacy of morphine analgesia in rats. *Diabetes* 1988; 37: 1253-9.
 46. Milan M, Herz A. The endocrinology of opioids. *Int Rev Neurobiol* 1985; 26: 1-83.
 47. Kolta MG, Soliman KF, Williams BB. Role of 5-hydroxytryptamine in the regulation of brain neuropeptides in normal and diabetic rat. *Horm Res* 1986; 23: 112-121.
 48. Iversen LL, Iversen SD, Snyder SH. Drugs, neurotransmitters and behavior. In: *Handbook of Psychopharmacology*, Plenum, New York; 1984 p 343- 395.
 49. Sewell RS, Spencer PS. The role of biogenic amines in the action of centrally acting analgesics, in: G. W. Ellis, GG. (Ed.), *Progress in medicinal chemistry*. 1977; 249-283.
 50. Taber RI, Latranyi MB. Antagonism of the analgesic effect of opioid and non-opioid agents by p-chlorophenylalanine (PCPA). *Eur J Pharmacol* 1981; 75: 215-222.
 51. Sajedianfard J, Khatami S, Semnani S, Naghdi N, Jorjani M. In vivo measurement of noradrenaline in the locus coeruleus of rats during the formalin test: a microdialysis study. *Eur J Pharmacol* 2005; 512: 153-156.
 52. Kawahara H, Kawahara Y, Westerink BH. The noradrenaline-dopamine interaction in the rat medial prefrontal cortex studied by multi-probe microdialysis. *Eur J Pharmacol* 2001; 418: 177-186.
 53. Fernstrom J.D. Food components to enhance performance: Stress and monoamine neurons in the brain. *National Academy Press, Washington, D.C.* 1994; 161- 176.
 54. Inase M, Nakahama H, Otsuki T, Fang JZ. Analgesic effects of serotonin microinjection into nucleus raphe magnus and nucleus raphe dorsalis evaluated by the monosodium urate (MSU) tonic pain model in the rat. *Brain-Res* 1987; 426: 205-211.
 55. Smith Y, Kievit JZ. Anatomy of the dopamine system in the basal ganglia. *Trends Neurosci* 2000; 23: 28- 33.
 56. Wood PB. Role of central dopamine in pain and analgesia. *Expert Review of Neurotherapeutics* 2008; 8: 781-797.
 57. Ohkubo Y, Nomura K, Yamaguchi I. Involvement of dopamine in the mechanism of action of FR64822, a novel non-opioid antinociceptive compound. *Eur J Pharmacol* 1991; 204:121-125.